ARTL ARTELO BIOSCIENCES, INC.
Price Chart
Executive Summary
Artelo Biosciences entered into a new $6.5M at-the-market (ATM) equity offering agreement with H.C. Wainwright, replacing its prior terminated facility with R.F. Lafferty. This comes amid a pending FINRA arbitration claim from Craft Capital Management seeking $880K in fees, and follows the recent termination of the prior ATM that raised only $451K under its predecessor. The new ATM opens an additional dilution path for a $4M market cap micro-cap with no revenue guidance.
Actionable Insight
The sequential ATM replacement and undisclosed FINRA arbitration create a negative signal. Monitor for rapid share sales under the new ATM (daily volume and announced sales), which would accelerate dilution. The arbitration claim at $1.76M (44% of market cap) is a material overhang. If the company draws aggressively on this ATM, expect further price erosion. Short sellers should watch for 8-K filings reporting ATM sales.
Key Facts
- Entered into new $6.5M ATM equity offering agreement with H.C. Wainwright on May 26, 2026
- Prior ATM with R.F. Lafferty was terminated on May 18, 2026, having raised only $451,527 from 50,858 shares
- Craft Capital Management filed a FINRA arbitration claim on April 7, 2026 seeking $880,000 success fee and $880,000 in warrants
- The company has a $4M market cap and no disclosed revenue-generating products
- Shelf registration S-3 was declared effective May 19, 2026; the ATM is incremental to the $69.3M unsold capacity already on the shelf
Financial Impact
Up to $6.53M in potential dilution at current market prices, representing more than 1.6x the company's $4M market cap. The prior ATM raised only $451K, but the new facility with H.C. Wainwright (a more aggressive placement agent) could be drawn more quickly. The Craft arbitration claim seeks up to ~$1.76M in fees/warrants against a $4M market cap.
Risk Factors
- Massive dilution potential: $6.5M ATM is 163% of current $4M market cap
- Pending FINRA arbitration claim for $880K fee + $880K warrants could trigger adverse judgment
- No revenue stream to offset cash burn; serial equity raises suggest capital needs exceed operating cash flow
- Zero analyst coverage (0 Strong Buy, 3 Hold, 6 Sell/Strong Sell) confirms lack of institutional confidence
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001640334-26-000973 |
| Document: artl_8k.htm | 0001640334-26-000973 |
| Document: artl_ex51.htm | 0001640334-26-000973 |
| Document: 0001640334-26-000973-index-headers.html | 0001640334-26-000973 |
| Document: 0001640334-26-000973-index.html | 0001640334-26-000973 |
| Document: 0001640334-26-000973.txt | 0001640334-26-000973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
18d ago
|
8-K
| $1.46 $1.46 | · 0.00% | ▼ −0.05% | $1.36 (+6.85%) |
|
May 18, 2026
27d ago
|
424B5
| $1.36 $1.40 | ▲ +2.57% | ▲ +0.33% | $1.36 (+0.00%) |
|
May 15, 2026
4w ago
|
8-K
| $1.46 $1.71 | ▲ +17.12% | ▲ +15.50% | $1.36 (−6.85%) |
|
May 14, 2026
4w ago
|
S-3/A
| $1.84 $1.19 | ▲ +35.33% | ▲ +36.29% | $1.36 (+26.09%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $3.57 $3.30 | ▼ −7.56% | ▼ −9.25% | $1.36 (−61.90%) |
|
Apr 20, 2026
8w ago
|
Press Release
| $4.53 $3.77 | ▼ −16.69% | ▼ −17.60% | $1.36 (−69.94%) |
|
Apr 7, 2026
9w ago
|
S-1
| $6.84 $5.31 | ▲ +22.37% | ▲ +25.89% | $1.36 (+80.12%) |
|
Apr 7, 2026
9w ago
|
8-K
| $7.29 $5.41 | ▼ −25.79% | ▼ −31.12% | $1.36 (−81.34%) |
|
Mar 31, 2026
10w ago
|
EFFECT
| $7.58 $6.84 | ▲ +9.76% | ▲ +13.71% | $1.36 (+82.06%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $7.58 $6.84 | ▲ +9.76% | ▲ +13.71% | $1.36 (+82.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access